WooGeneB&GCO.,Ltd Logo

WooGeneB&GCO.,Ltd

Manufactures veterinary medicines, vaccines, and supplements for livestock and aquatic animals.

018620 | KO

Overview

Corporate Details

ISIN(s):
KR7018620005
LEI:
Country:
South Korea
Address:
경기도 화성시 양감면 정문송산로 230, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

WooGene B&G Co., Ltd., founded in 1977, is a biotechnology company specializing in the manufacture and distribution of animal health products. The company's primary business involves developing veterinary medicines, vaccines, and feed supplements for livestock, including swine, poultry, and cattle, as well as for the aquatic animal industry. Its product portfolio features anti-infective drugs and anti-inflammatory enzymes. WooGene B&G utilizes advanced capabilities in microbial technology, large-scale pharmaceutical protein production, immunoassay techniques, and genome sequencing via its Baculovirus expression system. The company operates both in South Korea and internationally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-05-20 00:00
Major Shareholding Notification
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 31.4 KB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 102.9 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.7 KB
2025-03-28 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-27 00:00
Audit Report / Information
감사보고서제출
Korean 25.7 KB
2025-03-27 00:00
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
Korean 610.0 KB
2025-03-21 00:00
Report Publication Announcement
사업보고서제출기한연장신고서 (2024.12)
Korean 8.1 KB
2025-03-20 00:00
Regulatory News Service
기타경영사항(자율공시) (감사보고서 제출 지연)
Korean 7.5 KB
2025-03-12 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.0 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 9.9 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.9 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 183.3 KB
2025-03-12 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 191.1 KB

Automate Your Workflow. Get a real-time feed of all WooGeneB&GCO.,Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for WooGeneB&GCO.,Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for WooGeneB&GCO.,Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.